"3"^^ . . . . . . "0862-495X" . "Klinick\u00E1 onkologie" . "Celkem 31 pacient\u016F bylo v obdob\u00ED 06/ 2006\u2013 09/ 2009 l\u00E9\u010Deno jedn\u00EDm z inhibitor\u016F kin\u00E1z a sledov\u00E1no minim\u00E1ln\u011B 12 m\u011Bs\u00EDc\u016F. Hodnocen byl klinick\u00FD stav (v\u00FDvoj onemocn\u011Bn\u00ED, ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky, redukce d\u00E1vek) a p\u0159\u00EDm\u00E9 n\u00E1klady zaznamenan\u00E9 v komplexn\u00EDm onkologick\u00E9m centru (medikace, vy\u0161et\u0159en\u00ED, hospitalizace). V\u00FDsledky: Multikin\u00E1zov\u00E9 inhibitory byly u v\u011Bt\u0161iny pacient\u016F pod\u00E1ny v 2. linii l\u00E9\u010Dby; 1. lini\u00ED byl nej\u010Dast\u011Bji INF-alfa (86,7 %). N\u00E1klady na jeden m\u011Bs\u00EDc terapie do progrese onemocn\u011Bn\u00ED se pohybuj\u00ED pr\u016Fm\u011Brn\u011B ve v\u00FD\u0161i 94 141,8 K\u010D (sunitinib: doba do progrese 11 m\u011Bs\u00EDc\u016F, n\u00E1klady 1 267 648,5 K\u010D; sorafenib: doba do progrese 8 m\u011Bs\u00EDc\u016F, n\u00E1klady 896 670,1 K\u010D). Inkrement\u00E1ln\u00ED pom\u011Br n\u00E1kladov\u00E9 efektivity byl 123 659,5 K\u010D za m\u011Bs\u00EDc bez PD u pacient\u016F l\u00E9\u010Den\u00FDch sunitinibem vs sorafenibem. Ve f\u00E1zi progrese mRCC jsou m\u011Bs\u00ED\u010Dn\u00ED n\u00E1klady pr\u016Fm\u011Brn\u011B 45 767,0 K\u010D; u v\u00EDce ne\u017E poloviny pacient\u016F je po PD zvolena sekven\u010Dn\u00ED terapie (po selh\u00E1n\u00ED sunitinibu byl pod\u00E1n sorafenib a opa\u010Dn\u011B), ostatn\u00ED jsou l\u00E9\u010Deni pouze podp\u016Frnou medikac\u00ED. B\u011Bhem sledovan\u00E9ho obdob\u00ED zem\u0159elo 16 pacient\u016F, pr\u016Fm\u011Brn\u00E9 n\u00E1klady od pod\u00E1n\u00ED inhibitor\u016F kin\u00E1z do \u00FAmrt\u00ED (medi\u00E1n 12 m\u011Bs\u00EDc\u016F) byly 1 180 795,4 K\u010D. U \u010Dtvrtiny pacient\u016F nebyla dosud zaznamen\u00E1na progrese (medi\u00E1n doby bez progrese: sunitinib 18 m\u011Bs\u00EDc\u016F, sorafenib 14 m\u011Bs\u00EDc\u016F). Z\u00E1v\u011Br: Celkov\u00E9 n\u00E1klady na terapii pacient\u016F s mRCC jsou do progrese onemocn\u011Bn\u00ED z v\u00EDce ne\u017E 95 % tvo\u0159eny cenou l\u00E9ku, u progreduj\u00EDc\u00EDch pacient\u016F tvo\u0159\u00ED l\u00E9ky v\u00EDce ne\u017E 90 % celkov\u00FDch n\u00E1klad\u016F. Srovn\u00E1n\u00EDm prepar\u00E1t\u016F jsme zjistili, \u017Ee v 2. linii terapie mRCC lze za cenu 123 659,5 K\u010D dos\u00E1hnout jednoho m\u011Bs\u00EDce bez PD p\u0159i l\u00E9\u010Db\u011B sunitinibem ve srovn\u00E1n\u00ED se sorafenibem." . "23" . . "[9D77956E106F]" . "Celkem 31 pacient\u016F bylo v obdob\u00ED 06/ 2006\u2013 09/ 2009 l\u00E9\u010Deno jedn\u00EDm z inhibitor\u016F kin\u00E1z a sledov\u00E1no minim\u00E1ln\u011B 12 m\u011Bs\u00EDc\u016F. Hodnocen byl klinick\u00FD stav (v\u00FDvoj onemocn\u011Bn\u00ED, ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky, redukce d\u00E1vek) a p\u0159\u00EDm\u00E9 n\u00E1klady zaznamenan\u00E9 v komplexn\u00EDm onkologick\u00E9m centru (medikace, vy\u0161et\u0159en\u00ED, hospitalizace). V\u00FDsledky: Multikin\u00E1zov\u00E9 inhibitory byly u v\u011Bt\u0161iny pacient\u016F pod\u00E1ny v 2. linii l\u00E9\u010Dby; 1. lini\u00ED byl nej\u010Dast\u011Bji INF-alfa (86,7 %). N\u00E1klady na jeden m\u011Bs\u00EDc terapie do progrese onemocn\u011Bn\u00ED se pohybuj\u00ED pr\u016Fm\u011Brn\u011B ve v\u00FD\u0161i 94 141,8 K\u010D (sunitinib: doba do progrese 11 m\u011Bs\u00EDc\u016F, n\u00E1klady 1 267 648,5 K\u010D; sorafenib: doba do progrese 8 m\u011Bs\u00EDc\u016F, n\u00E1klady 896 670,1 K\u010D). Inkrement\u00E1ln\u00ED pom\u011Br n\u00E1kladov\u00E9 efektivity byl 123 659,5 K\u010D za m\u011Bs\u00EDc bez PD u pacient\u016F l\u00E9\u010Den\u00FDch sunitinibem vs sorafenibem. Ve f\u00E1zi progrese mRCC jsou m\u011Bs\u00ED\u010Dn\u00ED n\u00E1klady pr\u016Fm\u011Brn\u011B 45 767,0 K\u010D; u v\u00EDce ne\u017E poloviny pacient\u016F je po PD zvolena sekven\u010Dn\u00ED terapie (po selh\u00E1n\u00ED sunitinibu byl pod\u00E1n sorafenib a opa\u010Dn\u011B), ostatn\u00ED jsou l\u00E9\u010Deni pouze podp\u016Frnou medikac\u00ED. B\u011Bhem sledovan\u00E9ho obdob\u00ED zem\u0159elo 16 pacient\u016F, pr\u016Fm\u011Brn\u00E9 n\u00E1klady od pod\u00E1n\u00ED inhibitor\u016F kin\u00E1z do \u00FAmrt\u00ED (medi\u00E1n 12 m\u011Bs\u00EDc\u016F) byly 1 180 795,4 K\u010D. U \u010Dtvrtiny pacient\u016F nebyla dosud zaznamen\u00E1na progrese (medi\u00E1n doby bez progrese: sunitinib 18 m\u011Bs\u00EDc\u016F, sorafenib 14 m\u011Bs\u00EDc\u016F). Z\u00E1v\u011Br: Celkov\u00E9 n\u00E1klady na terapii pacient\u016F s mRCC jsou do progrese onemocn\u011Bn\u00ED z v\u00EDce ne\u017E 95 % tvo\u0159eny cenou l\u00E9ku, u progreduj\u00EDc\u00EDch pacient\u016F tvo\u0159\u00ED l\u00E9ky v\u00EDce ne\u017E 90 % celkov\u00FDch n\u00E1klad\u016F. Srovn\u00E1n\u00EDm prepar\u00E1t\u016F jsme zjistili, \u017Ee v 2. linii terapie mRCC lze za cenu 123 659,5 K\u010D dos\u00E1hnout jednoho m\u011Bs\u00EDce bez PD p\u0159i l\u00E9\u010Db\u011B sunitinibem ve srovn\u00E1n\u00ED se sorafenibem."@cs . . "CZ - \u010Cesk\u00E1 republika" . "A total of 31 patients were treated with sunitinib and/ or sorafenib between 06/ 2006 and 09/ 2009 and then followed for at least 12 months. Clinical (disease progression, adverse events, dose reduction) and cost data (medication, examination, hospitalization) were assessed in the comprehensive cancer centre (1Euro = 25.78 CZK). Results: The multikinase inhibitors were the second line treatment for most patients after INF-alfa therapy failure (86.7%). The mean cost per month to progression (PD) was 94,141.8 CZK/ 3,651.7 Euro (sunitinib: 11 months to PD, cost to PD 1,267,648.5 CZK/ 49,171.8 Euro; sorafenib: 8 months to PD, cost to PD 896,670.1 CZK / 34,781.6 Euro). The incremental cost-eff ectiveness ratio was 123,659.5 CZK / 4,796.7 Euro per progression-free month in sunitinib vs sorafenib patients. The mean cost per month after PD was 45,767.0 CZK/ 1,775.3 Euro with sequential therapy (sorafenib after sunitinib failure and vice- versa in more than half of patients) or best supportive care. 16 patients died during the study period with mean cost of 1,180,795.4 CZK/ 45,802.8 Euro per 12 months (median between treatment initiation with sunitinib or sorafenib and death). 8 patients (26%) did not achieve progression (median progression-free survival to 09/ 2009: sunitinib 18 months, sorafenib 14 months). Conclusion: The cost of medication made up more than 95% of total costs to PD and more than 90% after PD. The cost per progression-free month was 123,659.5 CZK/ 4,796.7 Euro in mRCC patients treated with sunitinib vs sorafenib."@en . . . "RIV/00209805:_____/10:#0000282!RIV12-MZ0-00209805" . "Anal\u00FDza n\u00E1klad\u016F na c\u00EDlenou biologickou l\u00E9\u010Dbu pacient\u016F s metastatick\u00FDm karcinomem ledvin" . . "Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma"@en . "Anal\u00FDza n\u00E1klad\u016F na c\u00EDlenou biologickou l\u00E9\u010Dbu pacient\u016F s metastatick\u00FDm karcinomem ledvin"@cs . . "Demlov\u00E1, Regina" . . "Kom\u00EDnek, Ji\u0159\u00ED" . . "RIV/00209805:_____/10:#0000282" . "246690" . "Anal\u00FDza n\u00E1klad\u016F na c\u00EDlenou biologickou l\u00E9\u010Dbu pacient\u016F s metastatick\u00FDm karcinomem ledvin" . "6" . . "I" . . "Anal\u00FDza n\u00E1klad\u016F na c\u00EDlenou biologickou l\u00E9\u010Dbu pacient\u016F s metastatick\u00FDm karcinomem ledvin"@cs . "Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma"@en . "7"^^ . "2"^^ . . "pharmacoeconomics; targeted therapy; sunitinib; sorafenib; renal cell carcinoma"@en . "Ondr\u00E1\u010Dkov\u00E1, Barbora" . .